New antibody injection could stop gout flares while lowering uric acid

NCT ID NCT07708181

Not yet recruiting Disease control Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study tests an experimental drug called SSGJ-613, a lab-made antibody, to prevent sudden gout attacks in people who are starting medication to lower uric acid. About 200 adults with frequent gout flares will receive either SSGJ-613 injections or standard colchicine pills for up to 24 weeks. The goal is to see if SSGJ-613 reduces the number of flares better than the current treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental anti-interleukin-1β antibody called SSGJ-613
What this could lead to: If successful, SSGJ-613 could offer a new way to prevent painful gout flares when starting urate-lowering therapy, potentially with fewer doses than daily pills.
What could go wrong: This is an early phase 2 trial with only 200 participants, so results may not apply to everyone. The drug's safety and effectiveness are still unproven, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arthritis, Gouty gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GOUT ARTHRITIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.